Pfizer
Pfizer
Beijing, China1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC | Non-Small Cell Lung Cancer ALK-positive | Active, not recruiting | Not stated | 2026-08-10 | NCT07556549 |